InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
1
T+90 hit rate
100%
T+90 mean return
+177.4%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Oltmans Curtis Gale, Vice-Président Senior, Conseiller Juridique. Director active across 2 companies, notably Fulcrum Therapeutics, Inc.. Aggregated, 3 reports have been recorded. Split: 1 buy · 1 sell. Total volume traded: €46k. Activity tracked since 28 June 2021. The latest transaction was disclosed on 15 December 2025 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Oltmans Curtis Gale
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
3,452 shares@ US$12.9282.2% of flowCommon StockSEC:0001193125-25-322740:0
49,020 shares0Common StockSEC:0001104659-21-152195:0
1,088 shares@ US$9.0117.8% of flowCommon StockSEC:0000899243-21-026556:0
Canonical exit: 26 Sept 2021 (T+90)
3 of 3 declarations
About Oltmans Curtis Gale
Oltmans Curtis Gale serves as Senior Vice President and General Counsel at Fulcrum Therapeutics, Inc. and Avenue Therapeutics, Inc. In this role, he oversees legal and regulatory matters while contributing to the overall strategy of the company. With expertise in corporate law, he plays a key role in managing legal risks and compliance. His experience in the pharmaceutical sector allows him to provide valuable insights into the company's strategic decisions.
